Keating Financial Advisory Services’s PharmaCyte Biotech PMCB Stock Holding History

Keating Financial Advisory Services’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$55	Buy	+7	New	+$73	﹤0.01%	2501

Other funds holding PMCB

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Equitec Proprietary Markets Chicago, Illinois $400M AUM 66.98% 1-Year Est. Return

GSC

Ground Swell Capital Folly Beach, South Carolina $43.4M AUM 20.78% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $83.6B AUM 19.78% 1-Year Est. Return

Keating Financial Advisory Services's PMCB Position: Q3 2026 in Review

Keating Financial Advisory Services opened a new position in PharmaCyte Biotech (PMCB) in Q3 2026: 7 shares worth $55. The stake represents ﹤0.01% of the portfolio and ranks #2501 among its holdings.

13 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

Keating Financial Advisory Services held 7 shares of PharmaCyte Biotech worth $55 as of Q3 2026.
PharmaCyte Biotech was a new Keating Financial Advisory Services position in Q3 2026.
PharmaCyte Biotech made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q3 2026, its #2501 holding.
13 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Keating Financial Advisory Services's 13F filing for Q3 2026, filed 12 Nov 2026.